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Abstract 
Objective: We have analyzed the association between clusterin expression in endometrial 
cancer cells and their resistance to paclitaxel. We also analyzed whether the effects of female 
sex hormones on clusterin expression by these cell lines affect their resistance to paclitaxel. 
Methods: The expression of estrogen receptors α and β, progesterone receptors AB and B, 
and clusterin mRNA and protein was assayed in the ECC-1 and KLE endometrial cancer cell 
lines by RT-PCR and Western blotting, respectively. The IC50 of paclitaxel was measured in 
each cell line by XTT assay. Using clusterin siRNA, we analyzed the association between 
clusterin expression and paclitaxel IC50 in each cell line. We also examined the effects of 
hormone treatment on cellular resistance to paclitaxel. Results: Paclitaxel IC50 was signifi-
cantly higher in KLE cells, which expressed higher levels of clusterin, than in ECC-1 cells, 
which expressed lower levels of clusterin. Conversely, incubation with clusterin siRNA sig-
nificantly decreased the viability of KLE cells (P<0.001), but did not alter the viability of ECC-1 
cells. Incubation with estrogen tended to increase the level of clusterin expression in these 
endometrial cancer cell lines, although the level of clusterin expression did not correlate with 
that of estrogen receptors. Incubation with progesterone did not alter the levels of expres-
sion of clusterin and clusterin receptor. Incubation with estrogen and paclitaxel significantly 
increased the viability of ECC-1 (P<0.001) but not KLE cells. Conclusion: Estrogen increases 
the paclitaxel resistance of endometrial cancer cell lines, by increasing clusterin expression. 
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Introduction 
Endometrial cancer is representative of hormone 
dependent  gynecologic  cancers  [1].  However,  at-
tempts  to  treat  female  hormone  dependent  cancers 
with  anti-hormonal  treatments  have  not  been  effec-
tive,  except  in  early  stage  cancers.  Although  the 
leading  cause  of  treatment  failure  was  drug  re-
sistance, the mechanisms by which these tumors be-
come resistant to chemotherapeutic agents have not 
been  clarified.  Tumors  in  patients  resistant  to  an-
ti-cancer  drugs  were  recently  reported  to  show  in-
creased expression of clusterin, which acts as a cyto-
protective protein of cancer cells [2]. 
The gene encoding clusterin is located on chro-
mosome 8p21-p12 [3]. Clusterin is a 75-80 kDa disul-
fide-linked heterodimeric protein that exists as several 
subtypes due to alternative splicing [4-7]. Clusterin is 
also known as TRPM-2 (testosterone repressed pros-
tate message- 2), SGP-2 (sulfated glycoprotien-2), and 
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Sp-40 and Apo-J (apoliprotein J) [4-7]. When the entire 
gene  is  expressed,  each  clusterin  molecule  is  ex-
pressed as an approximately 60 kDa precursor, which, 
after glycosylation, is converted to an approximately 
80 kDa secretory protein [8]. When exon 2 is spliced 
out  during  transcription,  however,  the  protein  syn-
thesized is approximately  55 kDa in size. Although 
the function of clusterin has not been determined, it is 
reported to act as a protective protein [9]. Clusterin is 
expressed in various cells and tissues and has been 
shown to function in cell adhesion and aggregation, 
complement  inhibition,  lipid  transport,  membrane 
protection and endocrine secretion [10, 11]. Clusterin 
overexpression has been reported in bladder, cervical, 
breast and prostate cancers [12-15]. For example, in an 
animal  model  of  androgen  independent  prostate 
cancer,  simultaneous  treatment  with  paclitaxel  and 
clusterin antisense-oligonucleotide enhanced the drug 
response rate [16]. Moreover, suppression of clusterin 
gene expression in prostate cancer cells was found to 
inhibit their proliferation and to enhance response to 
anticancer drugs [17]. However, there have been few 
studies on the effects of female hormones on clusterin 
expression in hormone dependent tumors. We there-
fore  evaluated  the  correlation  between  clusterin  ex-
pression  and  paclitaxel  resistance  in  hormone  de-
pendent endometrial cancer cell lines, as well as the 
effects of female hormones on clusterin expression. 
Material and methods 
1. Cell lines and culture conditions 
The  endometrial  cancer  cell  lines,  KLE  and 
ECC-1,  were  purchased  from  the  American  Type 
Culture  Collection  (ATCC,  Atlanta,  GA,  USA)  and 
were  cultured  in  RPMI1640  medium  (Gibco,  Grand 
Island, NY, USA) in a 5% CO2 environment. 
2. Investigation of gene expression 
1) RNA isolation and cDNA synthesis 
Total RNA was isolated from cultured cell lines 
using  TRIzol  reagent  (Invitrogen,  Carlsbad,  CA, 
USA). The cells were dissolved in TRIzol and centri-
fuged  after adding  bromochloropropane  (Sigma,  St. 
Louis, MO, USA). RNAs were precipitated with iso-
propanol, washed with ethanol to remove impurities, 
and  dissolved  in  DEPC  (diethyl  pyrocar-
bonate)-treated  distilled  water.  RNA  concentrations 
were  quantified  spectrophotometrically  (Thermo 
Fisher Scientific, IL, USA). To synthesize cDNA, RNA 
was incubated for 5 minutes at 70°C; Reverse Tran-
scription Master premix (Elpis, Taejeon, Korea) was 
added; and cDNA was synthesized by reverse tran-
scription for 60 minutes at 42°C, followed by inacti-
vation of the enzyme for 5 minutes at 94°C. 
2) Reverse transcription Polymerase chain reaction, 
RT-PCR 
Using PCR premixture (Promega, Madison, WI, 
USA), cDNA sequences encoding estrogen receptors α 
and β, progesterone receptors AB and B, and clusterin 
were amplified by PCR; a β-actin cDNA sequence was 
amplified  as  a  loading  control  (Table  1).  The  PCR 
products were electrophoresed in 1-2% agarose gels, 
and the amount in each band was quantitatively ana-
lyzed  using  the  Quantity  One  program  (Bio  Rad, 
Hercules, CA, USA). Each band was normalized rela-
tive to the β-actin band in the same sample. 
 
Table 1. Sequence of primers and PCR conditions. 






Clusterin  F  TTC CCA CAC TTC TGA 
CTC GGA C 
193  58 
  R  AAC ATC CAC ATC TCA 
CTC CTC C 
   
ER α  F  ATA CGA AAA GAC 
CGA AGA GGA G 
417  55 
  R  CCA GAC GAG ACC AAT 
CAT CA 
   
ER β  F  GGA TGA GGG GAA 
ATG CGT AGA A 
435  59 
  R  CCC GTG ATG GAG GAC 
TTG C 
   
PR AB  F  AGC CGG TCC GGG TGC 
AAG 
242  62 
  R  CCA CCC AGA GCC CGA 
GG 
   
PR B  F  ACT GAG CTG AAG GCA 
AAG GGT 
201  64 
  R  GTC CTG TCC CTG GCA 
GGG C 
   
β actin  F  GTG GGG CGC CCC AGG 
CAC CAG GGC 
540  58 
  R  CTC CTT AAT GTC ACG 
CAC GAT TTC 
   
 
3) Western blotting 
Proteins were extracted from cells using a lysate 
buffer  (Intron  Biotechnology,  Gyeonggi-Do,  Korea) 
and quantified by the Bradford assay. Aliquots con-
taining of 20 μg protein were electrophoresed on 10% 
SDS-PAGE  gels  for  2  hours  at  80  V.  Proteins  were 
transferred to PVDF membranes (Bio Rad) for 1 hour 
at 15 V using a Semi-Dry transfer unit (Bio Rad). Fol-
lowing  preincubation  with  a  blocking  agent,  the 
membranes were incubated with a monoclonal anti-
body  to  clusterin  (Millipore,  Temecula,  CA,  USA), 




ary  antibody.  As  a  loading  control,  the  membranes 
were incubated with a monoclonal antibody to β-actin 
(Cell Signaling, Danver, MA USA). Protein expression 
was developed using ECL (Enhanced chemilumines-
cence;  Thermo  Fisher  Scientific)  and  analyzed  with 
the Quantity One program (Bio Rad.)  
3. Paclitaxel IC50 (50% inhibitory concentra-
tion) 
Cells were placed in 96-well plates (1x104 cells 
per  well)  and  incubated  for  48  hours  with  various 
concentrations (10-4M ~ 10-12M) of paclitaxel (Hanmi, 
Gyeoggi-Do,  Korea).  Cell  proliferation  was  deter-
mined using XTT assays (cell proliferation kit; Roche, 
Mannheim, Germany), and the paclitaxel IC50 of each 
cell line was determined. 
4. Inhibition of clusterin expression using RNA 
interference 
Clusterin  siRNA  duplex,  consisting  of  nucleo-
tides +85 to +96 (where the translation start site was 
defined as +1; (Dharmacon Research, Lafayette, CO), 
or  luciferase  GL2  Duplex  (Dharmacon)  at  0.2 
nmol/ml  was  transfected  into  endometrial  cancer 
cells using oligofectamine reagent (Invitrogen, Carls-
bad, CA), as described by the manufacturer’s proto-
cols  (Life  Technologies,  Inc.,  Gaithersburg,  MD). 
Transfected cells were evaluated for clusterin expres-
sion and sensitivity to paclitaxel. 
5. Treatment with female hormones 
Cells were incubated with estrogen (β estradiol; 
Sigma), at concentrations of 0, 2, 20, 200, and 2000 nM, 
and progesterone (Sigma), at concentrations of 0, 2, 10, 
20, and 100  μM, for 24 hours, after which clusterin 
expression and drug resistance were analyzed.  
6. Treatment with female hormones and 
paclitaxel 
Cells  were  incubated  with  estrogen  or  proges-
terone, as above, for 24 hours. Paclitaxel was added 
and the cells were cultured for an additional 48 hours. 
XTT assays were performed, and cell survival rates 
were calculated. 
7. Statistical analysis. 
Groups were compared using Student’s t-tests. A 
P  value  less  than  0.001  was  defined  as  statistically 
significant. 
Results 
1. Hormone receptor and clusterin expression 
in endometrial cancer lines 
The expression in each cell line of hormone re-
ceptor  and  clusterin  mRNA  was  evaluated  using 
RT-PCR.  Only  ER  β  was  expressed  in  KLE  cells, 
whereas the ER α, ER β, PR AB, and PR B were all 
expressed  in  ECC-1  cells  (Figure  1).  The  levels  of 
clusterin mRNA expression were three-fold higher in 
KLE than in ECC-1 cells (Figure 2). 
 
 
Figure  1.  RT-PCR  of  ER  (Estrogen  receptor)  α,  β,  PR 
(Progesterone receptor) AB, B and β-actin in endometrial 
cancer cell lines (KLE, ECC-1). 
 
Figure 2. a. Western blotting of clusterin and β-actin in 
endometrial cancer cell line (KLE, ECC-1). b. The graph 
shows the ratio between the clusterin and  β-actin band 
density. 




2. Clusterin expression and resistance to 
paclitaxel. 
Cellular  resistance  to  paclitaxel  was  analyzed 
using XTT assays. We found that the paclitaxel IC50 
was  50-fold  higher  in  KLE  cells  (5X10-5M),  which 
showed a high level of clusterin mRNA expression, 
than in ECC-1 cells (10-6M), which showed a low level 
of clusterin expression. 
3. Inhibition of clusterin expression using 
siRNA and resistance to paclitaxel 
To determine whether clusterin expression was 
associated  with  sensitivity  to  paclitaxel,  we  trans-
fected  cells  with  clusterin  siRNA  and  analyzed  cell 
survival rate after treatment with paclitaxel. Suppres-
sion of clusterin expression in KLE cells was associ-
ated with a significant decrease in cell survival rate (P 
<0.001), whereas clusterin siRNA had no effect on the 
survival rate of ECC-1 cells (Figure 3). 
 
 
Figure 3. Cell survival ratio by XTT. Clusterin expression 
is inversely correlated with cytotoxic effects of paclitaxel. 
(*; P<0.001) White bars are treated siRNA luciferase as 
transfection  control  gene.  Blue  bars  are  treated  siRNA 
clusterin. 
4. Changes in clusterin expression during 
treatment with female hormones 
1) Estrogen treatment 
When KLE cells, which express the ER β recep-
tor, were treated with 200 nM and 2000 nM estrogen 
for 24 hours, the expression of clusterin protein in-
creased 23.0% and 22.3%, respectively, compared with 
untreated cells. Treatment of ECC-1 cells, which ex-
press the ER α and β receptors, with these same con-
centrations  of  estrogen  increased  the  expression  of 
clusterin  protein  by  46.9%  and  133.5%,  respectively 
(Figure 4). 
2) Progesterone treatment 
Treatment of KLE cells for 24 hours with 2, 10, 
and 20 μM progesterone increased clusterin protein 
expression  20.4%,  27.8%,  and  13.1%,  respectively, 
compared with untreated cells. However, incubation 
of  ECC-1  cells  with  progesterone  decreased  the  ex-
pression of clusterin protein (Figure 5). 
5. Effects of female hormones and paclitaxel 
on cell survival rates 
To analyze the effects of hormones on cell sensi-
tivity to paclitaxel, each cell line was pretreated with 
20 nM β estradiol for 24 hours, followed by treatment 
with paclitaxel for 48 hours, and their survival rates 
were  analyzed.  We  found  that  β  estradiol 
pre-treatment significantly increased the survival rate 
of ECC-1 (P <0.001), but not KLE, cells in response to 
paclitaxel treatment (Figure 6a). In contrast, preincu-
bation with 20 μM progesterone for 24 hours did not 
significantly alter the survival rates of both cell lines 
to treatment with paclitaxel (Figure 6b). 
 
 
Figure 4. Western blotting of clusterin, β-actin protein. Each cell line after treatment with the β estradiol (0, 2, 20, 200, 
2000nM) were Western blotting. a. KLE, b. ECC-1. The graph shows the ratio between the clusterin and β-actin band 





Figure 5. Western blotting of clusterin, β-actin protein. Each cell line after treatment with the progesterone (0, 2, 10, 20, 
100μM) were western blotting. a. KLE, b. ECC-1. The graph shows the ratio between the clusterin and β-actin band density. 
 
 
Figure  6. Comparison of cell survival ratio of hormone 
treatment alone and hormone with paclitaxel treatment. a. 
β estradiol, b. progesterone. (*; P<0.001) White bars are 
the hormones that a single treatment. Gray bars are treated 
with hormone and paclitaxel. 
Discussion 
Although  clusterin  was  first  isolated  in  1983 
from the testicular tissues of a lamb [10], its function 
has not yet been clearly identified [18]. Its presence in 
various  tumors  suggests  that  clusterin  inhibits 
cell-killing during cellular transformation and metas-
tasis [19-23]. In contrast, the expression of clusterin is 
reduced in some cancers, suggesting that this protein 
may  have  pro-apoptotic  activity  [24].  Its  activity  as 
both a pro- and anti-apoptotic protein has suggested 
that clusterin may be very important in the carcino-
genic  process.  When  expressed  in  secreted  form, 
clusterin  functions  as  an  anti-apoptosis  agent  [25], 
whereas, expressed in the nucleus, it functions as a 
pro-apoptosis factor [26]. Overexpression of clusterin 
during the treatment of patients with prostate, renal, 
breast and lung cancers has been closely associated 
with  resistance  to  anti-cancer  drugs,  including 
paclitaxel,  doxorubicin  and  cisplatin,  and  radiation 
treatments [17, 27-30]. 
The level of expression of clusterin protein was 
reported to be higher in the endometrioid than in the 
papillary  type  of  endometrial  cancer,  with  estrogen 
found to be associated with the regulation of clusterin 
protein  [31].  Clusterin  was  shown  to  have  an-
ti-apoptotic activity in breast cancer function [32] and 
to be associated with growth and metastasis in meta-
static breast cancer [33]. 
To clarify the association between clusterin ex-
pression  and  resistance  to  paclitaxel  in  endometrial 
cancer,  we  utilized  two  human  endometrial  cancer 




clusterin expression, respectively. We also compared 
the paclitaxel IC50 and clusterin expression in each cell 
line,  showing  that  KLE  cells  had  a  10-  to  50-fold 
higher IC50 than ECC-1 cells. After suppressing clus-
terin expression using a specific siRNA, we observed 
a close inverse association between clusterin expres-
sion and paclitaxel resistance, with  clusterin siRNA 
inducing a significant reduction in KLE cell survival 
rate after paclitaxel treatment, while having no effect 
on ECC-1 survival rate. These findings suggested that 
clusterin expression in endometrial cancer cell lines is 
associated  with  paclitaxel  resistance.  Treatment  of 
endometrial cancer cell lines with estrogen induced 
significant increases in clusterin protein expressions, 
especially  in  ECC-1  cells.  Incubation  of  these  cells 
with  200  nM  and  2000  nM  estrogen  increased  the 
clusterin  expression  2.03-  and  6.0-fold,  respectively. 
Moreover the survival rate of ECC-1 cells was higher 
after treatment with paclitaxel plus estrogen than af-
ter  treatment  with  paclitaxel  alone.  In  the  contrary, 
KLE  did  not  show  the  significant  difference.  These 
findings  suggested  that  estrogen  treatment  of  these 
cells is involved in resistance to paclitaxel by inducing 
the over-expression of clusterin. Furthermore, ECC-1 
has the ER α and β receptors but KLE has the only 
ER-α receptor. Although we did not evaluate whether 
estrogen up-regulated clusterin via ER α only or not, 
ER α may be more closely related with its mechanism 
than ER- β. 
Treatment of these endometrial cancer cell lines 
with progesterone did not induce consistent changes 
in clusterin expression, and treatment of these cells 
with progesterone and paclitaxel simultaneously had 
no  effect  on  survival  rates.  Although  progesterone, 
which  antagonizes  estrogen,  may  have  anti-cancer 
properties [34, 35], and 20 nM progesterone seemed to 
reduce cell survival rate, we found that progesterone 
did not significantly reduce the survival rate of these 
two cell lines. Progesterone, however, is likely associ-
ated with factors other than clusterin that may alter 
survival rates. 
In conclusion, we found that clusterin expression 
by endometrial cancer cell lines was closely associated 
with  their  resistance  to  anti-cancer  drugs.  Since  es-
trogen  is  associated  with  the  induction  of  clusterin 
expression,  estrogen  is  involved  in  the  mechanism 
that increases cellular resistance to paclitaxel. Assays 
of  clusterin  expression  in  endometrial  cancers  may 
predict their resistance to paclitaxel. In addition, in-
hibiting  clusterin  expression  in  endometrial  cancers 
may hold promise for the development of treatment 
methods. 
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